Abbott Laboratories (ABT) Profit Margins
Over the twelve months to 2026-06-30, Abbott Laboratories (ABT) had gross margin 56.6%, operating margin 15.8%, net margin 11.6%, free cash flow margin 16.8%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ABTAbbott LaboratoriesFollow ABT — free
—
Price chart with a free account
- Market cap
- 179.4B
- P/E TTM
- 33.5
- Dividend yield
- 2.4%
- 52-week
- —
- Next earnings
- 20 Jan, in 88 days
| Line | FY2009 Dec 09 | FY2010 Dec 10 | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 57.1% | 58.3% | 53.2% | 53.3% | 53.2% | 54.5% | 57.1% | 56.7% | 55.0% | 58.4% | 58.5% | 56.6% | 57.0% | 56.1% | 55.2% | 55.4% | 56.4% | 56.6% | |
| Operating margin | 20.3% | 17.3% | 7.6% | 7.1% | 10.9% | 12.8% | 14.1% | 14.5% | 5.7% | 11.9% | 14.2% | 15.5% | 19.6% | 19.2% | 16.2% | 16.3% | 18.2% | 15.8% | |
| Net margin | 18.7% | 13.2% | 22.1% | 31.3% | 13.1% | 11.3% | 21.7% | 6.7% | 1.7% | 7.7% | 11.6% | 13.0% | 16.4% | 15.9% | 14.3% | 31.9% | 14.7% | 11.6% | |
| FCF margin | 20.1% | 22.0% | 34.9% | 39.5% | 11.1% | 12.8% | 9.1% | 10.0% | 16.2% | 16.0% | 14.1% | 16.5% | 20.1% | 17.9% | 12.6% | 15.1% | 16.7% | 16.8% |
USD billions · SEC XBRL
Abbott Laboratories — questions
- What is Abbott Laboratories's gross margin?
- 56.6% over the twelve months to 2026-06-30.
- What is Abbott Laboratories's operating margin?
- 15.8% over the twelve months to 2026-06-30.
- What is Abbott Laboratories's net profit margin?
- 11.6% over the twelve months to 2026-06-30.
Every figure on this page comes from Abbott Laboratories's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.